Treatment Satisfaction, Symptom Control and Quality of Life (QoL) with Lanreotide Autogel (LAN) in NET Patients with Carcinoid Syndrome (CS): Results from the SYMNET Study Abstract #1178

Introduction: CS associated with NETs can have a negative impact on patients’ QoL.
Aim(s): To evaluate QoL data from the SYMNET study (NCT01234168).
Materials and methods: Primary endpoint was patient satisfaction with diarrhoea control. Symptoms assessed from medical records. QoL was assessed using the EORTC QLQ-C30 and QLQ-GI.NET21 questionnaires, which assess functional dimensions (QLQ C30) and symptoms (QLQ-C30 and QLQ-GI.NET21; lower scores = better QoL). Overall QoL was evaluated according to satisfaction with CS symptom control.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Philippe Ruszniewski
Keywords: quality of life

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1193 Health-Related Quality of Life (HRQoL) with Lanreotide Autogel (LAN) 120 mg in Patients with Enteropancreatic (EP-) NETs: Post Hoc Analyses from the CLARINET Study
Introduction: In CLARINET, favourable efficacy and safety with LAN in metastatic EP-NETs was associated with stable HRQoL outcomes.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Martyn Caplin
Authors: Caplin M, Pavel M, Cwikla J B, Phan A T, ...
#1676 NETTER-1 Phase III Trial: Recent Findings on Quality of Life in Patients with Midgut Neuroendocrine Tumors
Introduction: Impairment in quality of life caused by tumor load and hormone-related symptoms is frequent in GEP-NET patients. In the Phase III NETTER-1 trial, patients with advanced, progressive midgut NETs were randomized to treatment with 177Lu-DOTATATE (177Lu; Lutathera®) or high-dose (60 mg) Octreotide LAR (Oct).
Conference: 14th Annual ENETS conference (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Prof. Jonathan Strosberg
#2038 Overall Survival, Progression-Free Survival, and Quality of Life Updates from the NETTER-1 Study: 177Lu-Dotatate vs. High Dose Octreotide in Progressive Midgut Neuroendocrine Tumors
Introduction: The NETTER-1 final per-protocol statistical analysis (cut–off date 24.07.2015) of PFS, the primary endpoint of the study, showed a significant difference (p<0.0001) between the treatment arms.
Conference: 15th Annual ENETS conference (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Jonathan Strosberg
Authors: Strosberg J, Wolin E, Chasen B, Kulke M, ...
#456 Assessment of Quality of Life, Coping Strategies and Beliefs in NET Patients
Introduction: Quality of life (QoL) measurements have been included in clinical trials as a relevant outcome variable; however, other psychological variables might have an impact on QoL.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Mr Jorge Garcia-Hernandez
#951 SYMNET: A Study of Patient-Reported Outcomes (PROs) Associated with Lanreotide Autogel (LAN) for the Control of Carcinoid Syndrome (CS) Symptoms in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients (Pts)
Introduction: Somatostatin analogs can reduce incidence/severity of CS symptoms but their impact on pt satisfaction needs further investigation.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Professor Philippe Ruszniewski
Keywords: PRO